Key statistics dashboard for Anika Therapeutics, Inc. (ANIK). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies.
Stock Data
| Price | $20.84 |
| Market Cap | $279M |
| Enterprise Value | $266.3M |
| Beta | 0.28 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -77.94 |
| Price / Book | 2.05 |
| P/S | 2.33 |
| EV/EBITDA | 98.03 |
| EV/Sales | 2.21 |
| EV/FCF | 473.93 |
| P/FCF | 500.22 |
| Earnings Yield | -1.34% |
| FCF Yield | 0.20% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 62.16% |
| EBIT Margin | -2.41% |
| EBITDA Margin | 2.25% |
| Operating Margin | -4.24% |
| Net Margin | -3.14% |
| Return on Equity | -2.70% |
| Return on Assets | -2.06% |
| Return on Invested Capital | -3.17% |
| Return on Capital Employed | -3.17% |
Financial Health
| Current Ratio | 4.48 |
| Quick Ratio | 3.19 |
| Cash Ratio | 1.73 |
| Debt / Equity | 0.17 |
| Debt / Assets | 12.71% |
| Net Debt / EBITDA | -5.56 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 8.98 |
| Book Value per share | 10.22 |
| Cash per share | 2.86 |
| FCF per share | 0.04 |
| Tangible Book Value per share | 9.52 |
| Dividend per share | 0.00 |
Related companies: ANIX · APYX · ARAY · AVR · LNSR · LUCD · MXCT
Explore sector: Healthcare · Medical - Specialties
More sections of ANIK: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks